DOCSLIB.ORG

IMMUNOINFORMATICS: Bioinformatics Challenges In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IMMUNOINFORMATICS: Bioinformatics Challenges In Bioinformatics 1 -- Lecture 22 IMMUNOINFORMATICS: Bioinformatics Challenges in Immunology Most slides courtesy of Julia Ponomarenko, San Diego Supercomputer Center or Oliver Kohlbacher, WSI/ZBIT, Eberhard-Karls- Universität Tübingen The Immune Reaction 2 Vaccines have been made for 36 of >400 human pathogens Immunological Bioinformatics, 2005 The 4 MIT press. +HPV & Rotavirus Epitope Quantum unit of immunity Surface on which an antibody binds Comprises antigenic matter Linear epitope consists of a short AA sequence Conformational epitope depends on tertiary structure. 4 Two branches of immunity Innate Adaptive immunity immunity Recognizes molecules, called pathogen- Recognizes epitopes; that are specific associated molecular patterns (~103), or B- and T-cell recognition sites on PAMPs shared by groups of related antigens. microbes; e.g. LPS from the gram-negative cell wall, RNA from viruses, flagellin, and glucans from Is antigen-specific. fungal cell walls. 3 to 10 days response. Is antigen-nonspecific. Involves the following: Immediate or within several hours response. antigen-presenting cells (APCs) such as macrophages and dendritic cells; Involves body defense cells that have pattern-recognition receptors: . antigen-specific B-lymphocytes (~109); . Leukocytes: neutrophils, eosinophils, basophils . antigen-specific T-lymphocytes (~ and monocytes; 1012); and . cells that release inflammatory mediators: . cytokines. macrophages and mast cells; . natural killer cells (NK cells); and Improves with repeated exposure and . complement proteins and cytokines. becomes protective. Does not improve with repeated exposure to 3 a given infection. Components of the immune system 6 5 B and T cells recognize diferent epitopes of the same protein T-cell epitope B-cell epitope Denatured antigen Native or denatured (rare) antigen Linear (often) peptide 8-37 aa Sequential (continuous) or Internal (often) conformational (discontinuous) Accessible, hydrophilic, mobile, usually on the surface or could be Binding to T cell receptor: exposed as a result of -5 -7 physicochemical change Kd 10 – 10 M (low afnity) Binding to antibody: Slow on-rate, slow of-rate -7 -11 (once bound, peptide may stay Kd 10 – 10 M (high afnity) associated for hours to many days) Rapid on-rate, variable of-rate 11 B cell (magenta, orange) and T cell epitopes (blue, green, red) of hen egg-white lysozyme 10 PDB: 1dpx MHC class I pathway Intracellular pathogen (virus, mycobacteria) Cytosolic protein Proteasome Peptides CD8 TAP epitope ER ER MHC I TCR CD8 CTL (TCD8+) Any cell 13 Xenoreactive Complex AHIII 12.2 TCR bound to P1049 (ALWGFFPVLS) /HLA- MHC class I pathway A2.1 Intracellular pathogen T-Cell (virus, mycobacteria) Receptor Cytosolic protein V β Proteasome Vα Peptides CD8 TAP epitop ER ER e MHC I TCR MHC class I CD8 CTL (TCD8+) β-2- Any cell 14 Microglobulin 1lp9 MHC class I pathway Intracellular pathogen (virus, mycobacteria) Bioinformatics approaches at epitope prediction: Cytosolic protein (1) Prediction of proteosomal cleavage Proteasome sites (several methods exist based on small amount of in vitro data). Prediction of peptide-TAP binding Peptides (2) (ibid.). CD8 TAP epitop (3) Prediction of peptide-MHC ER ER e binding. MHC I TCR (4) Prediction of pMHC-TCR binding. CD8 CTL (TCD8+) Any cell 15 MHC class I epitope prediction: Challenges High rate of pathogen mutations. Pathogens evolve to escape: . Proteosomal cleavage (HIV); . TAP binding (HIV, HSV type I); . MHC binding. MHC genes are highly polymorphic (2,292 human alleles/1,670 - 2 yeas ago). MHC polymorphism is essential to protect the population from invasion by pathogens. But it generates problem for epitope-based vaccine design: a vaccine needs to contain a unique epitope binding to each MHC allele. Every normal (heterozygous) human expresses six diferent MHC class I molecules on every cell, containing α-chains derived from the two alleles of HLA-A, HLA-B, HLA-C genes that inherited from the parents. Every human has ~1012 lymphoid cells with a T-cell receptors repertoire of ~107 , depending on her immunological status (vaccinations, disease history, environment, etc.). 16 Prediction of MHC class I binding peptide – potential epitopes ALAKAAAAM ALAKAAAAN MHC allele or allele supertype (similar in sequences ALAKAAAAV alleles bind similar peptides) specific. ALAKAAAAT Peptide length (8-, 9-, 10-, 11-mers) specific. GMNERPILT Sequence-based approaches: GILGFVFTM . Gibbs sampling (when the training peptides are TLNAWVKVV of diferent lengths) KLNEPVLLL . Hidden Markov Models (ibid.) AVVPFIVSV . Sequence motifs, position weight matrices Peptides . Artificial Neural Networks (require a large known to number of training examples) bind to the HLA-A*0201 . SVM* molecule. 17 Performance measures for prediction methods Predicted score (binding afnity ROC curve 1.0 value) TP 0.8 FP 0.5 Score AUC FN threshold 0.3 or TN AROC True positive rate, TP / (TP + FN) / (TP positive rate, TP True 0 0 0.2 0.4 0.6 0.8 1 based on TP+FN – actual binders ( False positive rate, FP / (FP + TN) a defined threshold on binding afnity values) TN+ FP – actual non-binders (ibid.) Sensitivity = TP / (TP + FN) = 6/7= 0.86 Specificity = TN / (TN + FP) = 6/8 = 0.75 18 Performance measures for prediction methods (cont) Predicted score pi (binding afnity Pearson’s correlation value) coefcient TP FP Score FN threshold TN TP+FN – actual binders (based on a defined threshold on actual binding afnity values ai ) TN+ FP – actual non-binders (ibid.) Sensitivity = TP / (TP + FN) = 6/7= 0.86 19 Specificity = TN / (TN + FP) = 6/8 = 0.75 MHC class I pathway MHC class II pathway Intracellular pathogen (virus, mycobacteria) Extracellular protein Cytosolic protein Endosome Proteasome ? Peptides MHC II CD8 TAP epitope CD4 epitope ER ER MHC I TCR TCR CD4 CD8 CTL TCD4+ (TCD8+) Any cell B-cell, macrophage, or dendritic cell29 Complex Of A Human TCR, Influenza HA Antigen Peptide (PKYVKQNTLKLAT) and MHC Class II MHC class I pathway MHC class II pathway T-Cell Intracellular pathogen (virus,Receptor mycobacteria) Extracellular protein Cytosolic protein Endosome Proteasome Vα V β ? Peptides MHC II TAP CD4 MHC class II ER ER epitop α e MHC I TCR MHCT classCD8+ II CD4 TCD4+ β Any cell B-cell, macrophage, or dendritic cell30 Complex Of A Human TCR, Influenza HA Xenoreactive Complex AHIII 12.2 TCR Antigen Peptide (PKYVKQNTLKLAT) and MHC bound to P1049 (ALWGFFPVLS) /HLA- Class II A2.1 Epitope, or antigenic determinant, is T-Celldefined as the site of an antigen recognized by immune response T-Cell Receptormolecules (antibodies, MHC, TCR) Receptor T cell epitope – a short linear peptide or other chemical entity (native or denatured antigen) that binds MHC V β (class I binds 8-10 ac peptides; classV αII Vα bindsV β 11-25 ac peptides) and may be recognized by T-cell receptor (TCR). TMHC cell recognition of antigen involves tertiaryclass IIcomplex α “antigen-TCR-MHC”. MHC class I MHC class II β β-2- 31 1fyt Microglobulin 1lp9 MHC class II epitope prediction: Challenges Complex Of A Human TCR, Influenza HA MHC class II genes are as highly Antigen Peptide (PKYVKQNTLKLAT) and polymorphic as MHC class I (1,012 MHCExtracellular Class II protein human alleles for today). T-Cell The repertoire of T-cell receptors ReceptorEndosome is ~107 and depends on an individual’s immunological status (vaccinations, disease history, environment, etc.). ? MHC II Vα The epitope length 9-37 aa. V The peptide may have non-linear β CD4 conformation. epitope MHC The MHC binding groove is open class II from both sides and it is known α that residues outside the groove efect peptide binding. TMHCCD4+ class II B-cell, macrophage, or dendriticβ cell32 MHC class II epitope prediction: Challenges Extracellular protein Endosome The processing of MHC class II epitopes is still a mystery and likely depends on the antigen structure, the ? cell type and other factors. MHC II CD4 epitope TCR CD4 TCD4+ B-cell, macrophage, or dendritic cell33 22 Prediction of MHC class II binding peptide – potential epitopes MHC allele or allele supertype (similar in sequences alleles bind similar peptides) specific. Predictions for peptides of length 9 aa (the peptide-MHC binding core) Sequence-based approaches: . Gibbs sampling . Sequence motifs, position weight matrices . Machine learning: SVM, HMM, evolutionary algorithms 35 Nielsen et al., Bioinformatics 2004 Benchmarking predictions of peptide binding to MHC II (Wang et al. PLoS Comput Biol. 2007) Data: pairs {peptide – afnity value in terms of IC50 nM} for a given MHC allele 16 diferent mouse and human MHC class II alleles. 10,017 data points. 9 diferent methods were evaluated: 6 matrix-based, 2 SVM, 1 QSAR-based. AUC values varied from 0.5 (random prediction) to 0.83, depending on the allele. Comparison with 29 X-ray structures of peptide-MHC II complexes (14 diferent alleles): . The success level of the binding core recognition was 21%-62%, . with exception of TEPETOPE method (100%) that is based on structural information and measured afnity values for mutant variants of MHC class II and peptides (Sturniolo et al., Nature Biotechnology, 1999). => Structural information together with peptide-MHC binding data should improve the prediction. 36 38 26 ] 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 Outstanding problems in TAP/ Proteosome/MHC peptide prediction High throughput data generation . Currently few verified peptide sequences. Overfitting likely Something better than the usual machine learning approach? . Structure-based motifs, length preferences? . Combine multiple motifs, reflecting multiple enzymes? Vaccine design to incorporate cleavage motifs . Optimize recombinant vaccine for cleavage? 63 Cellular immunity 64 65 Epitope-based vaccines A major reason for analyzing and predicting epitopes is because they may lead to the development of peptide-based synthetic vaccines. Thousands of peptides have been pre-clinically examined; over 100 of them have progressed to phase I clinical trials and about 30 to phase II, including vaccines for foot-and-mouth virus infection, influenza, HIV.
Load more

Recommended publications
  • Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins
    viruses Article Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins 1, , 2, 1 Viviana C. Zomosa-Signoret * y , Karina R. Morales-González y, Ana E. Estrada-Rodríguez , Ana M. Rivas-Estilla 1 , M. Cristina Devèze-García 2, Edgar Galaviz-Aguilar 2 and 2, , Román Vidaltamayo * y 1 Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey NL 64460, Mexico; [email protected] (A.E.E.-R.); [email protected] (A.M.R.-E.) 2 Departament of Basic Science, School of Medicine, Universidad de Monterrey, Av. Ignacio Morones Prieto 4500 Pte, Garza García NL 66238, Mexico; [email protected] (K.R.M.-G.); [email protected] (M.C.D.-G.); [email protected] (E.G.-A.) * Correspondence: [email protected] (V.C.Z.-S.); [email protected] (R.V.); Tel.: +52-81-1340-4000 (V.C.Z.-S.); +52-81-8215-1444 (R.V.) These authors contributed equally to this work. y Received: 10 December 2019; Accepted: 7 February 2020; Published: 13 February 2020 Abstract: The expansion of the habitat of mosquitoes belonging to the Aedes genus puts nearly half of the world’s population at risk of contracting dengue fever, and a significant fraction will develop its serious hemorrhagic complication, which can be fatal if not diagnosed properly and treated in a timely fashion. Although several diagnostic methods have been approved for dengue diagnostics, their applicability is limited in rural areas of developing countries by sample preparation costs and methodological requirements, as well as cross-reactivity among the different serotypes of the Dengue virus and other flavivirus, such as the Zika virus.
    [Show full text]
  • Antibodies That Neutralize Human I8 Interferon Biologic Activity Recognize a Linear Epitope: Analysis by Synthetic Peptide Mappi
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 4040-4044, May 1991 Immunology Antibodies that neutralize human I8 interferon biologic activity recognize a linear epitope: Analysis by synthetic peptide mapping (multiple peptide synthesis/"pepscan"/monoclonal antibodies) PHILIP N. REDLICH*t, PAUL D. HOEPRICH, JR.t§, C. BUDD COLBYt, AND SIDNEY E. GROSSBERG*¶ Departments of *Microbiology and tSurgery, The Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226; and tTriton Biosciences, 1501 Harbor Bay Parkway, Alameda, CA 94501 Communicated by Duard L. Walker, December 28, 1990 (received for review June 12, 1990) ABSTRACT The location of biologically relevant epitopes T-cell epitopes important in the biologic activity of viral and on recombinant human fi interferon in which Ser-17 replaces plasmodial proteins (22-26). Cys-17 (rh[Ser17JIFN-_l) was evaluated by testing the immuno- To map the location of epitopes identified by a panel of reactivity of antibodies against 159 sequential, overlapping mAbs raised against recombinant Ser-17-substituted hIFN-p8 octamer peptides. Three monoclonal antibodies (mAbs) that (rh[Ser17]IFN-f3) (17, 18), we determined their reactivity with neutralize rh[Ser'7]IFN-fl biologic activity, designated Al, A5, sequential, overlapping octamer peptides spanning the entire and A7, bound to peptides spanning only residues 3948, length ofthe rh[Ser17]IFN-,8 molecule. The panel consisted of whereas nonneutralizing mAb bound less specifically at mul- neutralizing (A) and nonneutralizing (B) mAbs that identify tiple sites near the amino terminus. The immunoreactivity of three functionally and immunochemically distinct epitopes, peptides spanning residues 40-47 that contained a series of designated sites I, Il, and III.
    [Show full text]
  • Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-Cov-2 Spike Protein
    Article Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein Junping Hong 1,2,†, Qian Wang 1,2,†, Qian Wu 1,2,†, Junyu Chen 2, Xijing Wang 1,2, Yingbin Wang 2,*, Yixin Chen 1,2,* and Ningshao Xia 1,2 1 National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361102, China; [email protected] (J.H.); [email protected] (Q.W.); [email protected] (Q.W.); [email protected] (X.W.); [email protected] (N.X.) 2 State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China; [email protected] * Correspondence: [email protected] (Y.W.); [email protected] (Y.C.) † These authors have contributed equally to this work. Abstract: To date, SARS-CoV-2 pandemic has caused more than 188 million infections and 4.06 million deaths worldwide. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein has been regarded as an important target for vaccine and therapeutics development because it plays a key role in binding the human cell receptor ACE2 that is required for viral entry. However, it is not easy to detect RBD in Western blot using polyclonal antibody, suggesting that RBD may form a complicated conformation under native condition and bear rare linear epitope. So far, no linear epitope on RBD is reported. Thus, a monoclonal antibody (mAb) that recognizes linear epitope on RBD will become valuable.
    [Show full text]
  • 1 Epitope-Based Chimeric Peptide Vaccine Design Against S, M and E Proteins of SARS-Cov-2
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.30.015164; this version posted March 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 2 etiologic agent of global pandemic COVID-19: an in silico approach 3 4 M. Shaminur Rahman1*, M. Nazmul Hoque1,2*, M. Rafiul Islam1*, Salma Akter1,3, A. S. M. 5 Rubayet-Ul-Alam1,4, Mohammad Anwar Siddique1, Otun Saha1, Md. Mizanur Rahaman1**, 6 Munawar Sultana1, M. Anwar Hossain1,5** 7 1Department of Microbiology, University of Dhaka, Dhaka 1000, Bangladesh 8 2Department of Gynecology, Obstetrics and Reproductive Health, Bangabandhu Sheikh Mujibur 9 Rahman Agricultural University, Gazipur-1706, Bangladesh 10 3Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh 11 4Department of Microbiology, Jashore University of Science and Technology, Jashore 7408, 12 Bangladesh 13 5Present address: Vice-Chancellor, Jashore University of Science and Technology, Jashore 7408, 14 Bangladesh 15 *Equal contribution 16 **Corresponding to: 17 18 M. Anwar Hossain, PhD 19 Professor 20 Department of Microbiology 21 University of Dhaka, Dhaka, Bangladesh 22 E-mail: [email protected] 23 Or, 24 Dr. Md. Mizanur Rahaman 25 Assistant Professor 26 Department of Microbiology 27 University of Dhaka, Dhaka, Bangladesh 28 E-mail: [email protected] 29 30 31 32 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.30.015164; this version posted March 31, 2020.
    [Show full text]
  • Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-Cov-2 Virion Proteins for Vaccine Development
    Article Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development 1, 1, 2 1, , Andrés Corral-Lugo y, Mireia López-Siles y , Daniel López , Michael J. McConnell * z 1, , and Antonio J. Martin-Galiano * z 1 Intrahospital Infections Unit, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), 28220 Madrid, Spain; [email protected] (A.C.-L.); [email protected] (M.L.-S.) 2 Immune Presentation and Regulation Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain; [email protected] * Correspondence: [email protected] (M.J.M.); [email protected] (A.J.M.-G.); Tel.: +34-91-822-3869 (M.J.M.); +34-91-822-3976 (A.J.M.-G.) These authors contributed equally to this work. y These authors contributed equally to this work. z Received: 18 May 2020; Accepted: 17 July 2020; Published: 20 July 2020 Abstract: The efficacy of SARS-CoV-2 nucleic acid-based vaccines may be limited by proteolysis of the translated product due to anomalous protein folding. This may be the case for vaccines employing linear SARS-CoV-2 B-cell epitopes identified in previous studies since most of them participate in secondary structure formation. In contrast, we have employed a consensus of predictors for epitopic zones plus a structural filter for identifying 20 unstructured B-cell epitope-containing loops (uBCELs) in S, M, and N proteins. Phylogenetic comparison suggests epitope switching with respect to SARS-CoV in some of the identified uBCELs. Such events may be associated with the reported lack of serum cross-protection between the 2003 and 2019 pandemic strains.
    [Show full text]
  • A Convenient Synthetic Method to Improve Immunogenicity of Mycobacterium Tuberculosis Related T-Cell Epitope Peptides
    Article A Convenient Synthetic Method to Improve Immunogenicity of Mycobacterium tuberculosis Related T-Cell Epitope Peptides Kata Horváti 1,2,* , Bernadett Pályi 3, Judit Henczkó 3, Gyula Balka 4, Eleonóra Szabó 5, Viktor Farkas 6 , Beáta Biri-Kovács 1,2 ,Bálint Szeder 7 and Kinga Fodor 8 1 MTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, Hungarian Academy of Sciences, Budapest 1117, Hungary 2 Institute of Chemistry, Eötvös Loránd University, Budapest 1117, Hungary 3 National Biosafety Laboratory, National Public Health Center, Budapest 1097, Hungary 4 Department of Pathology, University of Veterinary Medicine, Budapest 1078, Hungary 5 Laboratory of Bacteriology, Korányi National Institute for Tuberculosis and Respiratory Medicine, Budapest 1122, Hungary 6 MTA-ELTE Protein Modelling Research Group, Eötvös Loránd University, Hungarian Academy of Sciences, Budapest 1117, Hungary 7 Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest 1117, Hungary 8 Department of Laboratory Animal and Animal Protection, University of Veterinary Medicine, Budapest 1078, Hungary * Correspondence: [email protected] Received: 27 June 2019; Accepted: 20 August 2019; Published: 27 August 2019 Abstract: Epitopes from different proteins expressed by Mycobacterium tuberculosis (Rv1886c, Rv0341, Rv3873) were selected based on previously reported antigenic properties. Relatively short linear T-cell epitope peptides generally have unordered structure, limited immunogenicity, and low in vivo stability. Therefore, they rely on proper formulation and on the addition of adjuvants. Here we report a convenient synthetic route to induce a more potent immune response by the formation of a trivalent conjugate in spatial arrangement. Chemical and structural characterization of the vaccine conjugates was followed by the study of cellular uptake and localization.
    [Show full text]
  • Linear B-Cell Epitope Prediction for in Silico Vaccine Design: a Performance Review of Methods Available Via Command-Line Interface
    International Journal of Molecular Sciences Review Linear B-Cell Epitope Prediction for In Silico Vaccine Design: A Performance Review of Methods Available via Command-Line Interface Kosmas A. Galanis , Katerina C. Nastou †, Nikos C. Papandreou, Georgios N. Petichakis, Diomidis G. Pigis and Vassiliki A. Iconomidou * Section of Cell Biology and Biophysics, Department of Biology, School of Sciences, National and Kapodistrian University of Athens, 15701 Athens, Greece; [email protected] (K.A.G.); [email protected] (K.C.N.); [email protected] (N.C.P.); [email protected] (G.N.P.); [email protected] (D.G.P.) * Correspondence: [email protected]; Tel.: +30-210-727-4871; Fax: +30-210-727-4254 † Present Address: Novo Nordisk Foundation Center of Protein Research, University of Copenhagen, Blegdamsvej 3B, 2200 København, Denmark. Abstract: Linear B-cell epitope prediction research has received a steadily growing interest ever since the first method was developed in 1981. B-cell epitope identification with the help of an accurate prediction method can lead to an overall faster and cheaper vaccine design process, a crucial necessity in the COVID-19 era. Consequently, several B-cell epitope prediction methods have been developed over the past few decades, but without significant success. In this study, we review the current performance and methodology of some of the most widely used linear B-cell epitope predictors which are available via a command-line interface, namely, BcePred, BepiPred, ABCpred, COBEpro, Citation: Galanis, K.A.; Nastou, K.C.; SVMTriP, LBtope, and LBEEP. Additionally, we attempted to remedy performance issues of the Papandreou, N.C.; Petichakis, G.N.; individual methods by developing a consensus classifier, which combines the separate predictions of Pigis, D.G.; Iconomidou, V.A.
    [Show full text]
  • AN IMMUNOINFORMATICS STUDY to PREDICT EPITOPES in the ENVELOPE PROTEIN of SARS-COV-2 Renu Jakhar¹ and S.K Gakhar2
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.26.115790; this version posted May 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. AN IMMUNOINFORMATICS STUDY TO PREDICT EPITOPES IN THE ENVELOPE PROTEIN OF SARS-COV-2 Renu Jakhar¹ and S.K Gakhar2 1, 2Centre for Medical Biotechnology, Maharshi Dayanand University, Rohtak -124001, Haryana 1Corresponding Author- Renu Jakhar Centre for Medical Biotechnology Maharshi Dayanand University Rohtak -124001, Haryana. Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.05.26.115790; this version posted May 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract COVID-19 is a new viral emergent human disease caused by a novel strain of Coronavirus. This virus has caused a huge problem in the world as millions of the people are affected with this disease in the entire world. We aimed to design a peptide vaccine for COVID-19 particularly for the envelope protein using computational methods to predict epitopes inducing the immune system and can be used later to create a new peptide vaccine that could replace conventional vaccines. A total of available 370 sequences of SARS-CoV-2 were retrieved from NCBI for bioinformatics analysis using Immune Epitope Data Base (IEDB) to predict B and T cells epitopes.
    [Show full text]
  • Epitope-Based Peptide Vaccine Against Severe Acute Respiratory Syndrome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.16.100206; this version posted May 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Epitope-Based Peptide Vaccine Against Severe Acute Respiratory Syndrome- Coronavirus-2 Nucleocapsid Protein: An in silico Approach Ahmed Rakib1, Saad Ahmed Sami1, Md. Ashiqul Islam1,2, Shahriar Ahmed1, Farhana Binta Faiz1, Bibi Humayra Khanam1, Mir Muhammad Nasir Uddin1, Talha Bin Emran3,4* 1Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong- 4331, Bangladesh 2Department of Pharmacy, Mawlana Bhashani Science & Technology University, Santosh, Tangail-1902, Bangladesh 3Drug Discovery, GUSTO A Research Group, Chittagong-4000, Bangladesh 4Department of Pharmacy, BGC Trust University Bangladesh, Chittagong-4381, Bangladesh *Correspondence: Dr. T.B. Emran [email protected] [email protected] Running title: In silico vaccine design against SARS-CoV-2 nucleocapsid protein 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.16.100206; this version posted May 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract With an increasing fatality rate, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has emerged as a promising threat to human health worldwide. SARS-CoV-2 is a member of the Coronaviridae family, which is transmitted from animal to human and because of being contagious, further it transmitted human to human.
    [Show full text]
  • Mapping the Conformational Epitope of a Neutralizing Antibody (Acv1) Directed Against the Acmnpv GP64 Protein ⁎ Jian Zhou A,B, Gary W
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Virology 352 (2006) 427–437 www.elsevier.com/locate/yviro Mapping the conformational epitope of a neutralizing antibody (AcV1) directed against the AcMNPV GP64 protein ⁎ Jian Zhou a,b, Gary W. Blissard a, a Boyce Thompson Institute, Cornell University, Tower Road, Ithaca, NY 14853, USA b Department of Entomology, Cornell University, Ithaca, NY 14853, USA Received 10 March 2006; returned to author for revision 10 April 2006; accepted 24 April 2006 Available online 14 June 2006 Abstract The envelope glycoprotein GP64 of Autographa californica nucleopolyhedrovirus (AcMNPV) is necessary and sufficient for the acid-induced membrane fusion activity that is required for fusion of the budded virus (BV) envelope and the endosome membrane during virus entry. Infectivity of the budded virus (BV) is neutralized by AcV1, a monoclonal antibody (MAb) directed against GP64. Prior studies indicated that AcV1 recognizes a conformational epitope and does not inhibit virus attachment to the cell, but instead inhibits entry at a step following virus attachment. We found that AcV1 recognition of GP64 was lost upon exposure of GP64 to low pH (pH 4.5) and restored by returning GP64 to pH 6.2. In addition, the AcV1 epitope was lost upon denaturation of GP64 in SDS, but the AcV1 epitope was restored by refolding the protein in the absence of SDS. Using truncated GP64 proteins expressed in insect cells, we mapped the AcV1 epitope to a 24 amino acid region in the central variable domain of GP64.
    [Show full text]
  • Pepperprint Epitope Mapping Solutions
    A Disruptive New Technology for Epitope Mapping! Only PEPperPRINT’s unique peptide microarray platform enables you to identify and map epitopes from antibodies and sera with unrivalled epitope resolution from single to hundreds of antigens at once order custom microarrays with up to 30,000 high fidelity peptides reliably receive your custom peptide microarrays within 3-5 weeks adjust your microarray from chip to chip and obtain rapid readouts benefit from the highest signal-to-noise ratios available cover protein conformations and posttranslational modifications Here are some examples of PEPperPRINT’s epitope mapping microarray applications: Linear and conformational epitope mappings for therapeutic antibodies in numerous development projects of various top 10 pharma companies Antibody cross-reactivity analyses for biopharmaceutical discovery projects Validation of diagnostic antibodies for an international diagnostics company In-depth specificity analysis of various anti-HLA-E research antibodies What our customers say: "Besides the fact that the data is useful to us, it remains as a fact that the quality of the testing is outstanding. The epitope is mapped." Patrizio Giacomini, Ph.D., (Assisstant Professor) Regina Elena National Cancer Institute, Rome "We have used the ‘Epitope Mapping Service’ from PEPperPRINT and the quality of results produced and professionalism of the service surpassed our expectations. The results obtained are very useful for our research and I would not hesitate to use this service in the future or to recommend it to fellow researchers working in the field." Javier Castillo-Olivares, Ph.D., (Fellow) Orbivirus Immunology, The Pirbright Institute, Woking “Congratulations to the whole PEPperPRINT team for the final report that is an example of clarity and good knowledge." Antonio Toniolo, M.D., (Professor of Medical Microbiology) FAMH, University of Insubria “The results are very clear and perfectly documented.
    [Show full text]
  • Docktope: a Web-Based Tool for Automated Pmhc-I Modelling
    www.nature.com/scientificreports OPEN DockTope: a Web-based tool for automated pMHC-I modelling Maurício Menegatti Rigo1,*, Dinler Amaral Antunes1,2,*, Martiela Vaz de Freitas1, Marcus Fabiano de Almeida Mendes1, Lindolfo Meira3, Marialva Sinigaglia1 & 1 Received: 28 June 2015 Gustavo Fioravanti Vieira Accepted: 18 November 2015 The immune system is constantly challenged, being required to protect the organism against a wide Published: 17 December 2015 variety of infectious pathogens and, at the same time, to avoid autoimmune disorders. One of the most important molecules involved in these events is the Major Histocompatibility Complex class I (MHC-I), responsible for binding and presenting small peptides from the intracellular environment to CD8+ T cells. The study of peptide:MHC-I (pMHC-I) molecules at a structural level is crucial to understand the molecular mechanisms underlying immunologic responses. Unfortunately, there are few pMHC-I structures in the Protein Data Bank (PDB) (especially considering the total number of complexes that could be formed combining different peptides), and pMHC-I modelling tools are scarce. Here, we present DockTope, a free and reliable web-based tool for pMHC-I modelling, based on crystal structures from the PDB. DockTope is fully automated and allows any researcher to construct a pMHC-I complex in an efficient way. We have reproduced a dataset of 135 non-redundant pMHC-I structures from the PDB (Cα RMSD below 1 Å). Modelling of pMHC-I complexes is remarkably important, contributing to the knowledge of important events such as cross-reactivity, autoimmunity, cancer therapy, transplantation and rational vaccine design. The immune system is mainly responsible for defending the organism against a wide range of infectious patho- gens, such as viruses, bacteria and fungi.
    [Show full text]